Stocks & ETFs

Latest News

Blogs & Articles

Stratagy Backtesting

Portfolio Analyser

Price Analyser

Compare Stocks

Stock & ETF Screener

Pricing

About The Company

CEO

Mr. Erik J. Deitsch

Market Cap

759.68 Thousand USD

Sector

Healthcare

Website

https://www.nutrapharma.com

Description

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States.

Read More

Overview

Value

26

Growth

73

Health

28

Management

42

Analyst Opinion

74

Total

49

All Scores Out Of 100

Best Features

  • Very strong cashflow and earnings growth
  • Has a low level of debt
  • Price-to-earnings ratio of 0.1 is lower than the market average (19.6x)
  • Liked by analysts
  • Low preportion of income is paid as dividend

Risk Factors

  • Earnings growth has slowed down recently
  • Income is not covering expenditure and investment
  • There is a history of diluting shareholders
  • 0
  • Does not hold enough liquid assets to cover short term liabilities
  • Poor overall financial health
  • No margin of safety at their current market price
  • 0

Market Peers

NPHC

Key Figures

PE Ratio (TTM)

0.13

Margin Of Safety (DCF)

-2206.91%

Revenue Growth (5 Year Average)

18.98%

Ratings Consensus

Buy

Share Buybacks

-7.16%

Dividend Yeild (TTM)

N/A

Valuation

Value Score

26

  • Price-to-earnings ratio of 0.1 is lower than the market average (19.6x)
  • Estimated intrinsic-value of NaN undefined USD is lower than current price ( 100.00 undefined USD)
  • Free-cashflow-yeild of -110.17% is worse than the market average (4.7%)
  • Margin-of-safety of -2206.91% is worse than the market average (17.95%)

Desired Margin Of Safety

0%

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Buy Target: N/A

Current Price: 0 USD

Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.

Price/Earnings

0.13x

Free Cashflow Yeild

-110.17%

PE/Earnings Growth

0.00

Price/Book

-0.06x

Growth

Growth Score

73

  • 5 Year Average Revenue growth of 18.98% is higher than the market average (10.97%)
  • Revenue growth has improved this yeara
  • 5 Year Average Earnings growth of 24.53% is higher than the market average (14.48%)
  • 5 Year Average Cashflow growth of 15.98% is higher than the market average (12.35%)
  • Free Cashflow growth has improved this year
  • Earnings growth has slowed this year

Revenue Growth

18.98%

Earnings Growth

24.53%

Cashflow Growth

15.98%

Health

Health Score

28

  • Has a low level of debt
  • Cashflow is negative
  • 0
  • Assets do not cover liabilities
  • High financial leverage and base interest rate exposure
  • Requires debt for normal operation to be sustainable
  • Debt repayments significantly impact cashflow

Altman Z Score

N/A

Piostroski Score

6.00

Debt/Equity

N/Ax

Current Assets/Liabilities

0.03x

Free Cashflow/Total Debt

N/Ax

Debt/Capital

18.16x

Management

Management Score

42

  • Has issued new shares to finance growth when share price is high
  • Return-on-capital-employed of 4.74% is lower than the market average (10%)
  • Has a history of diluting shareholders to finance activity
  • Return-on-equity of N/A is lower than the market average (15%)

Average Buybacks/Dilution

-7.16%

Recent Buybacks/Dilution

0.06%

5 Year Price Volitility

N/A

Return On Assets

N/A

Return On Capital Employed

4.74%

Return On Equity

N/A

Return On Free Cashflow

N/A

Return On Investments

N/A

Analysts

Analyst Opinion

74

  • Ratings consensus is Buy

SEC Filings

Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

Other Information

Company Name

Nutra Pharma Corp.

Currency

USD

Beta

0.471921

Vol Avg

667622

Ceo

Mr. Erik J. Deitsch

Cik

0001119643

Cusip

67060U208

Exchange

Other OTC

Full Time Employees

4

Industry

Drug Manufacturers—Specialty & Generic

Sector

Healthcare

Ipo Date

2013-01-02

Address

1537 NW 65th Avenue

City

Plantation

State

FL

Country

US

Zip

33313

Phone

954 509 0911

All financial data provided by FMP

Noticed an error with something on our site?

We Use Cookies